Kymera Therapeutics (KYMR) EBIAT (2019 - 2025)
Kymera Therapeutics (KYMR) has disclosed EBIAT for 7 consecutive years, with -$87.0 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT fell 22.94% to -$87.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$311.4 million, a 39.08% decrease, with the full-year FY2025 number at -$311.4 million, down 39.08% from a year prior.
- EBIAT was -$87.0 million for Q4 2025 at Kymera Therapeutics, down from -$82.2 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$13.1 million in Q1 2021 to a low of -$87.0 million in Q4 2025.
- A 5-year average of -$46.9 million and a median of -$41.5 million in 2023 define the central range for EBIAT.
- Peak YoY movement for EBIAT: surged 58.79% in 2023, then crashed 392.43% in 2024.
- Kymera Therapeutics' EBIAT stood at -$33.9 million in 2021, then dropped by 2.85% to -$34.9 million in 2022, then soared by 58.79% to -$14.4 million in 2023, then crashed by 392.43% to -$70.8 million in 2024, then fell by 22.94% to -$87.0 million in 2025.
- Per Business Quant, the three most recent readings for KYMR's EBIAT are -$87.0 million (Q4 2025), -$82.2 million (Q3 2025), and -$76.6 million (Q2 2025).